98%
921
2 minutes
20
Opioid-induced overdose is one of the leading causes of death among the US population under the age of 50. In 2021 alone, the death toll among opioid users rose to a devastating number of over 80,000. The overdose process can be reversed by the administration of naloxone, an opioid antagonist that rapidly counteracts the effects of opioid-induced respiratory depression. The idea of a closed-loop opioid overdose detection and naloxone delivery has emerged as a potential engineered solution to mitigate the deadly effects of the opioid epidemic. In this work, we introduce a wrist-worn wearable device that overcomes the portability issues of our previous work to create a closed-loop drug-delivery system, which includes (1) a Near-Infrared Spectroscopy (NIRS) sensor to detect a hypoxia-driven opioid overdose event, (2) a MOSFET switch, and (3) a Zero-Voltage Switching (ZVS) electromagnetic heater. Using brachial artery occlusion (BAO) with human subjects (n = 8), we demonstrated consistent low oxygenation events. Furthermore, we proved our device's capability to release the drug within 10 s after detecting a hypoxic event. We found that the changes in the oxyhemoglobin, deoxyhemoglobin and oxygenation saturation levels ( SpO) were different before and after the low-oxygenation events ( 0.001). Although additional human experiments are needed, our results to date point towards a potential tool in the battle to mitigate the effects of the opioid epidemic.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920833 | PMC |
http://dx.doi.org/10.1109/TBCAS.2023.3331272 | DOI Listing |
N Engl J Med
September 2025
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst.
Background: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
Methods: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.
J Workplace Behav Health
August 2025
Division of Field Studies and Engineering, National Institute for Occupational Safety and Health.
Firefighters often serve as emergency medical services providers and face repeated exposure to potentially traumatic events (PTEs) while participating in opioid overdose responses (OORs), which may impact their mental health. A survey of 173 firefighters who had participated in an OOR in the previous 6 months was used to assess exposure to PTEs during such events, job stress, mental health symptoms, and resources used to address mental health symptoms. Most firefighters (97%) reported experiencing one or more PTEs while responding to an opioid overdose in the past 6 months.
View Article and Find Full Text PDFAm J Psychiatry
September 2025
Michigan Innovations in Addiction Care Through Research and Education (MI-ACRE) Program, Department of Psychiatry, University of Michigan, Ann Arbor.
Objective: While opioid overdose has begun to decrease in recent years, stimulant overdose has continued to increase and has not been adequately addressed. Unlike opioid use disorder, there are no medications approved by the U.S.
View Article and Find Full Text PDFPerm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFAm J Prev Med
September 2025
Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Pleasanton, CA, United States.
Introduction: Prescription opioid dose reductions can raise the risk of adverse events for patients on long-term opioid therapy for non-cancer pain. Evidence on whether risks differ by age or sex is needed to support tailored clinical decision-making.
Methods: In 2024, a secondary analysis of an observational cohort study was conducted across 8 U.